Fate therapeutics appoints brian t. powl as chief commercial officer

San diego, june 30, 2022 (globe newswire) -- fate therapeutics, inc. (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that brian t. powl has been appointed chief commercial officer. mr. powl brings to fate therapeutics extensive commercial leadership experience in hematologic malignancies and solid tumors, having previously served as the global commercial car t lead at celgene corporation where he oversaw the commercial development strategy of the company's car t-cell therapies.
FATE Ratings Summary
FATE Quant Ranking